| Title |
Progesterone receptor loss identifies hormone receptor-positive and HER2-negative breast cancer subgroups at higher risk of relapse: a retrospective cohort study
|
|---|---|
| Published in |
OncoTargets and therapy, March 2016
|
| DOI | 10.2147/ott.s98666 |
| Pubmed ID | |
| Authors |
Jia-Yuan Sun, San-Gang Wu, Feng-Yan Li, Huan-Xin Lin, Zhen-Yu He |
| Abstract |
To assess the prognostic value of progesterone receptor (PR) expression in patients with hormone receptor-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer subgroups. A retrospective review of breast cancer patients who underwent mastectomy or breast-conserving surgery between January 1998 and December 2007 was performed. The prognostic impact of PR status on disease-free survival (DFS) was analyzed. Of the 1,301 patients included in this study, the median follow-up time was 64 months, and the median age was 46 years. There were 18.4% of patients (n=219) with PR negative (PR-) cancer. Women with PR-breast cancer were more likely to be postmenopausal (P<0.001) and have pN3 stage (P=0.031) and Stage III (P=0.049) cancer. Cox regression univariate and multivariate analysis showed that PR status was a significant prognostic factor for DFS. Patients with PR- status had poorer DFS (hazard ratio =1.626, 95% confidence interval =1.060-2.497, P=0.026). The 5-year DFS for patients with PR- and PR+ breast cancer was 79.4% and 86.2%, respectively, and the 8-year DFS for patients with PR- and PR+ breast cancer was 69.6% and 78.1%, respectively (P=0.012). A significant difference in DFS was observed between PR- and PR+ disease in patients with node-negative cancer, but was not for patients with lymph node metastasis (P=0.242). In premenopausal patients, DFS varied significantly by PR status (P=0.049). A marginally significant difference in DFS between the PR- and PR+ disease was seen in postmenopausal patients (log rank P=0.065). Lack of PR expression is associated with worse survival in patients with hormone receptor-positive and HER2-negative breast cancer subgroups. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 29 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 7 | 24% |
| Researcher | 4 | 14% |
| Student > Ph. D. Student | 4 | 14% |
| Lecturer > Senior Lecturer | 1 | 3% |
| Other | 1 | 3% |
| Other | 2 | 7% |
| Unknown | 10 | 34% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 31% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 10% |
| Agricultural and Biological Sciences | 3 | 10% |
| Biochemistry, Genetics and Molecular Biology | 2 | 7% |
| Computer Science | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 10 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 April 2016.
All research outputs
#22,759,452
of 25,373,627 outputs
Outputs from OncoTargets and therapy
#2,078
of 3,016 outputs
Outputs of similar age
#269,143
of 312,604 outputs
Outputs of similar age from OncoTargets and therapy
#75
of 108 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 312,604 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 108 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.